Article

Don’t split hairs when it comes to subspecialties

Author(s):

Jon Carter

© Jon Carter 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Related Content
Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases
May 19th 2025

Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
May 16th 2025

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
November 1st 2024

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

Hypoglycemia may promote a breakdown of the blood-retinal barrier
May 13th 2025

Hypoglycemia may promote a breakdown of the blood-retinal barrier

Beacon Therapeutics shares 6-month interim safety and efficacy results from Phase 2 DAWN study for XLRP
May 8th 2025

Beacon Therapeutics shares 6-month interim safety and efficacy results from Phase 2 DAWN study for XLRP

© 2025 MJH Life Sciences

All rights reserved.